Literature DB >> 31840387

Survival outcomes of hepatic resections in Bismuth-Corlette type IV cholangiocarcinoma.

Dominic Ku1,2, Reuben Tang1, Tony Pang1,2, Henry Pleass1,2, Arthur Richardson1,2, Lawrence Yuen1,2, Vincent Lam1,2,3.   

Abstract

BACKGROUND: Surgical resection for Bismuth-Corlette type IV (BC-IV) hilar cholangiocarcinomas, also termed Klatskin tumours are technically challenging and were once considered unresectable tumours. Following advances in hepatobiliary imaging and surgical techniques, emerging evidence suggests that surgical resection is a viable avenue for long-term survival. We aimed to identify factors affecting survival outcomes of hepatic resections for BC-IV cholangiocarcinomas.
METHOD: A systematic review was performed across multiple databases and several clinical trial registries. Two reviewers independently screened and selected papers that contained survival data on BC-IV cholangiocarcinoma after hepatic resections.
RESULTS: Of 13 499 papers from our search result, 21 papers satisfied the inclusion criteria. The median post-operative survival was 30.8 months. The average 1- and 5-year post-operative survivals were 61.6 and 33.3%, respectively. Predictors of long-term survival included achievement of R0 margins, minimisation of operative time and reduction intra-operative blood loss.
CONCLUSION: Our analysis demonstrates improving post-operative outcomes and survival in surgical resection of BC-IV cholangiocarcinoma and suggests that radical surgical resection is a valid treatment option for the disease.
© 2019 Royal Australasian College of Surgeons.

Entities:  

Keywords:  bile duct neoplasm; cholangiocarcinoma; hepatectomy; hilar carcinoma; survival outcome

Mesh:

Substances:

Year:  2019        PMID: 31840387     DOI: 10.1111/ans.15531

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  2 in total

1.  Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry.

Authors:  Lynn E Nooijen; Jesus M Banales; Marieke T de Boer; Chiara Braconi; Trine Folseraas; Alejandro Forner; Waclaw Holowko; Frederik J H Hoogwater; Heinz-Josef Klümpen; Bas Groot Koerkamp; Angela Lamarca; Adelaida La Casta; Flora López-López; Laura Izquierdo-Sánchez; Alexander Scheiter; Kirsten Utpatel; Rutger-Jan Swijnenburg; Geert Kazemier; Joris I Erdmann
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

2.  Improving Outcomes in Perihilar Cholangiocarcinoma.

Authors:  Karl J Oldhafer; Thomas von Hahn; Marianna Arvanitakis; Masato Nagino; Orlando J M Torres
Journal:  Visc Med       Date:  2021-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.